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Strategies to achieve an R0 resection
• Staged resection
• Portal vein embolization
• Hepatic artery infusion / chemoembolization
• Focused radiotherapy 
• Radiofrequency ablation
• Neoadjuvant chemotherapy
Laparoscopic evaluation of patient 
with colorectal liver metastases 
• Lymph node positive primary
• CEA > 200 ng/ml
• Disease free interval < 12 months
• > 1 liver metastasis
• Metastasis > 8 cm
Patients with 2 or more factors have 30% 
chance of extrahepatic intraperitoneal disease
Grobmyer Arch Surg 2004; 139: 1326-1330

Neuroendocrine liver metastases
• Untreated 5 year survival rate 30%
• Best option: complete resection of primary lesion 
and liver metastasis – 5YSR 46-93%
• Octreotide may control growth and symptoms
• Octreotide linked therapies may target lesions
• Incomplete resection may reduce symptoms
• Transplantation possible in select situations
• Adjuvant chemotherapy not indicated 
Non-colorectal, non-neuroendocrine 
(NCNN) metastases
• Autopsy studies show 10 -15% of patients with 
NCNN mets have disease confined to the liver
• Mathematical analysis of the frequency of mets 
in various tissues suggest liver, lung and bone 
are staging sites for further spread
• Liver mets appear to be less sensitive to 
chemotherapy than lesions elsewhere
Non-colorectal, non-neuroendocrine liver metastectomy
Study PI (year) No. patients 5 yr survival Favourable prognostic factors
Harrison (1997) 96 37% Ro, non-GI primary, DFI>36m
Elias (1998) 127 40% Ro, non-GI, non-melanoma
Lang (1999) 127 25% Ro
Hemming (2000) 37 45% Ro, non-GI primary
Laurent (2001) 39 35% DFI>24m
Cordera (2005) 64 30% DFI>24m
Weitz (2005) 141 36% Ro, reproductive tract, DFI>24m
Ercolani (2005) 142 34% Ro, non-GI
Adapted from Advanced Therapy in Surgical Oncology 2008 Pollock, 
Curley, Ross, Perrier (eds)
Non-colorectal, non-neuroendocrine 
(NCNN) metastases
• Ro resection more important than number of 
lesions
• Disease free interval > 24 months
• Resected NCNN mets with prognosis similar to 
colorectal mets: gynecological, urological, breast 
and sarcoma
• Resected NCNN mets with poor prognosis: 
biliary, pancreatic, gastric, esophageal
• Multimodality treatment (assume 
micrometastases elsewhere)
